Literature DB >> 10596699

Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages.

Y Sugiyama1, K Yanagisawa, S I Tominaga, S Kitamura.   

Abstract

Low-dose long-term erythromycin treatment has recently been reported to be very effective in patients with chronic respiratory infection and inflammation. This effect of erythromycin was thought to be not antibacterial but anti-inflammatory. However, the exact mechanism of the effect of erythromycin has not yet been clarified. The aims of this study were to investigate the effects of erythromycin on cytokine production and its mechanisms of actions in rat alveolar macrophages. Using rats with or without administration of erythromycin for 3 months, the production of the cytokines tumour necrosis factor-or (TNF-alpha), cytokine-induced neutrophil chemoattractant (CINC)-1 and CINC-2alpha by enzyme-linked immunosorbent assay and the expression of TNF-alpha and CINC-1 messenger ribonucleic acid (mRNA) by Northern blotting in rat alveolar macrophages were analysed. CINC-1 is the rat counterpart of human interleukin-8, and CINC-2alpha of human macrophage inflammatory peptide-2. Erythromycin reduced cytokine production and secretion when cytokines was induced by lipopolysaccharide treatment. Conversely, erythromycin slightly upregulated the expression of cytokine mRNA. These results suggest that erythromycin inhibits cytokine production and exhibits anti-inflammatory effects by means of a translational and/or posttranslational mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596699     DOI: 10.1183/09031936.99.14511139

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

Review 2.  New and emerging therapies for pulmonary complications of cystic fibrosis.

Authors:  M R Tonelli; M L Aitken
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.

Authors:  T Ichiyama; M Nishikawa; T Yoshitomi; S Hasegawa; T Matsubara; T Hayashi; S Furukawa
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Nobuko Araki; Koichi Yamada; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

Review 5.  Treatment of chronic rhinosinusitis with low-dose, long-term macrolide antibiotics: an evolving paradigm.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

6.  Low-dose, long-term macrolide therapy in asthma: An overview.

Authors:  Umur Hatipoglu; Israel Rubinstein
Journal:  Clin Mol Allergy       Date:  2004-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.